Monaldi Hospital, Naples, Italy
Copyright 2016, American College of Chest Physicians. All Rights Reserved.
SESSION TITLE: COPD Pharmacotherapy
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: To evaluate the effectiveness of the aclidinium bromide (322 mcg twice a day) in improving nocturnal oxygen saturation in COPD patients (B-C stages).
METHODS: We examined 100 patients, all affected by the same COPD severity according to GOLD guidelines (B-C stages). All patients, at the enrolment, filled in a questionnaire on the presence of the following symptoms: a) excessive daytime sleepiness; b) choking or gaspingduring sleep; c) recurrent awakenings from sleep; d) unrefreshing sleep; e) daytime fatigue; f) morning headaches; g) nicturia. We studied the nocturnal oxygen saturation of patients who presented symptoms. 45 patients had sleep disordered breathing with desaturation. All 45 patients were treated aclidinium bromide (322 mcg twice a day). Patients were re-evaluated after 15 days of treatment.
RESULTS: The results, after 15 days of treatment, showed a significant improvement of all parameters examined, particularly of saturation time under 90%. All patients have reported improvement in daytime symptomatology.
CONCLUSIONS: Our study suggest a positive role of aclidinium bromide in improving nocturnal oxygen saturation in patient with COPD.
CLINICAL IMPLICATIONS: Anticholinergic drugs, commonly used in COPD treatment for the bronchodilation improving, were studied in the last years about their effectiveness in sleeping oxygen desaturations. The quality of life is significantly worse in COPD patients with sleep disorders. Therefore the improvement of the nocturnal oxygen saturation is a necessary objective. The study is ongoing, and further evaluation is needed to confirm results.
DISCLOSURE: The following authors have nothing to disclose: Giuseppe Fiorentino, Anna Annunziata, Gianfranco Scotto di Frega, Rosa Cauteruccio, Antonella Marotta, Mariantonietta Mazza
No Product/Research Disclosure Information
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.